Budget impact analysis of delgocitinib for moderate to severe Chronic Hand Eczema in the United States [0.03%]
德加西替尼治疗美国中重度手部湿疹患者的预算影响分析
Jianni Singh-Landa,Aseel Bin Sawad,Yasmin Bappoo et al.
Jianni Singh-Landa et al.
Background: Chronic Hand Eczema (CHE) is an inflammatory skin disease defined as eczema affecting the hands and/or wrists lasting >3 months and/or re-occurring ≥2 times per year. Delgocitinib cream 20 mg/g, a topical jan...
A systematic review of acute and long-term outcomes in patients with non-transvenous implantable cardioverter-defibrillators [0.03%]
非经静脉植入型心脏复律除颤器患者的急性及长期预后系统评价
Steven Zweibel,David Lanctin,Reece Holbrook et al.
Steven Zweibel et al.
Background: Non-transvenous implantable cardioverter-defibrillator (ICD) systems have been developed to address limitations of transvenous ICDs. This systematic literature review aimed to summarize periprocedural and long...
Economic burden associated with switching from frontline pegaspargase or calaspargase pegol to second-line recombinant Erwinia in pediatrics and adolescents/young adults with acute lymphoblastic leukemia [0.03%]
一线培甘司明或培沙如帕诱导失败后转为二线重组埃维菌素治疗儿童、青少年及年轻成人急性淋巴细胞白血病的经济负担分析
Meghan McCormick,Tina Gu,Tarun Bhagnani et al.
Meghan McCormick et al.
Aims: This study aims to quantify costs and healthcare resource utilization (HCRU) associated with switching from frontline (1 L) pegaspargase (PEG)/calaspargase pegol (CAL-PEG) to second-line (2 L) recombinant Erwinia in...
Beyond direct medical costs: what we miss when indirect costs are ignored [0.03%]
超越直接医疗成本：忽视间接成本时所遗漏的事项
Urszula Religioni,Rocío Barrios-Rodríguez,Pilar Requena et al.
Urszula Religioni et al.
Cost-effectiveness of vagus nerve-mediated neuroimmune modulation for the treatment of moderate-to-severe rheumatoid arthritis [0.03%]
迷走神经刺激治疗中重度类风湿性关节炎的成本效益分析
Ellen L Air,Anne M Ryschon,Joshua M Rosenow et al.
Ellen L Air et al.
Aims: Rheumatoid arthritis (RA) is associated with increased healthcare resource utilization and high-cost pharmacologic treatment. The objective of the current analysis was to evaluate the cost-effectiveness of vagus ner...
CPAP treatment persistence following nasal procedures in obstructive sleep apnea: a real-world claims-based analysis of 1.3 million patients [0.03%]
基于真实世界理赔数据的疗效分析：鼻部手术后阻塞型睡眠呼吸暂停患者持续使用CPAP治疗情况（纳入130万例病人）
Atul Malhotra,Mas Takashima,Andrew Vahabzadeh-Hagh et al.
Atul Malhotra et al.
Objective: To evaluate the association between nasal procedures and long-term continuous positive airway pressure (CPAP) treatment persistence in a large US administrative claims database. ...
2025 in review: high-impact articles from the Journal of Medical Economics [0.03%]
2025年回顾：《医疗经济学杂志》高影响力文章精选
Ivo Abraham,Mike Gregg
Ivo Abraham
Cost-effectiveness analysis of xanomeline and trospium chloride for the treatment of adults with schizophrenia in the US [0.03%]
美国成人精神分裂症患者使用盐酸氨磺必利和托特罗定治疗的成本效益分析
Tyler Mantaian,Kristin Gillard,Jonathan Kowalski et al.
Tyler Mantaian et al.
Aim: The objective of this analysis was to evaluate the cost-effectiveness of xanomeline and trospium chloride (KarXT) as first line (1 L) treatment for adults with schizophrenia from a third-party US payer perspective co...
Correction [0.03%]
改正犯错
Published Erratum
Journal of medical economics. 2026 Dec;29(1):1421-1422. DOI:10.1080/13696998.2026.2668301 2026